We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Article

Stay Up-to-Date With COVID-19 Drug Development

Rectangle Image
Article

Stay Up-to-Date With COVID-19 Drug Development

Read time:
 

Researchers are working tirelessly to design new drugs and repurpose existing drugs against the novel coronavirus SARS-CoV-2.



Below, you'll find a list of our latest COVID-19 drug-related coverage.

Drug Reduces SARS-CoV-2 Infection by Up to 70% in Cell-Based Screen


Masitinib Inhibits the Replication of SARS-CoV-2 in Preclinical Models


Small Trials Suggest Ivermectin May Have Sizeable Effects on COVID-19 Mortality

Considerations When Designing COVID-19 Drug Trials

COVID-19: 160 Drugs Identified That Could Be Repurposed

Treating COVID-19: Protein Engineering Approach Could Accelerate Drug Discovery

Compounds Reduce SARS-CoV-2 Replication in Cultured Cells

Certain Gut Bacteria Produce Compounds That Inhibit SARS-CoV-2

Drug Duo Combats SARS-CoV-2 in Cell Culture Models

Several Existing Drugs Possess Antiviral Activity Against SARS-CoV-2

Computational Tool Helps Find Molecules With COVID-19-Fighting Properties

Organ Chip-Based Testing Supports Rapid Drug Repurposing for COVID-19

Hepatitis C Drugs Boost Remdesivir’s Ability To Inhibit SARS-CoV-2 in Cell Culture

"Nanotraps" Designed To Catch and Clear Coronavirus

Experimental Drug MK-4482 for COVID-19 Is Effective in Hamster Study

Fragment Screen Points to New SARS-CoV-2 Inhibitors

A Long-Acting Injectable Therapy To Treat COVID-19

Asthma Drug Reduces Recovery Time in Non-Hospitalized Patients With COVID-19

Nine Potential New COVID-19 Treatments

Phase 1 Study of Novel Oral Antiviral Against SARS-CoV-2 Initiated

“Silencing” nsp14 Protein To Weaken SARS-CoV-2

Unexpected Binding Between SARS-CoV-2 and Antiviral Drug

Anti-SARS-CoV-2 Drug Candidate Enters Phase 1 Trial in the US

Anti-Androgen Drugs May Disarm COVID-19 Spike Protein

Leprosy Drug Exhibits Potent Antiviral Activities Against SARS-CoV-2

A Potential Target for Anti-COVID-19 Therapies

NIH Closes Enrolment for Two Sub-Studies in ACTIV-3 Trial

Team Discovers Drug Candidates That Can Stop SARS-CoV-2 Replication

Four Potential COVID-19 Drugs Enter Phase 2/3 Testing

Budesonide Reduces Need for Hospitalization in COVID-19 Patients, Phase 2 Study Suggests

Anticancer Drug May Speed Up Recovery of Patients With Severe COVID-19

How Vitamins, Steroids and Antiviral Drugs May Affect SARS-CoV-2

Anticancer Drug Demonstrates Activity Against SARS-CoV-2, Including B.1.1.7 Variant in the Lab

Potential Target for Anti-Viral Drugs To Treat COVID-19

Pilot Study Suggests That Ivermectin Can Help To Treat Mild COVID-19

Two Existing Drugs Could Improve Survival in Patients With Severe COVID-19

Treating COVID-19: Baricitinib Plus Remdesivir Shows Promise in Trial

Drug Rapidly Blocks SARS-CoV-2 Transmission in Animal Model

Team Discovers Inhibitors Capable of Blocking the Uptake of SARS-CoV-2

Creating Drugs To Inhibit SARS-CoV-2 Entry and Replication Simultaneously

Aspirin Being Investigated as a Possible Treatment for COVID-19

Study Suggests That Beta-Blockers Could Be Used To Treat COVID-19

Deep Learning Model Helps Drug Developers Target SARS-CoV-2's Main Protease

FDA Approves Remdesivir for COVID-19

Accelerated Screen Identifies 25 Existing Drugs Capable of Disrupting SARS-CoV-2 Cell Entry

Could Amodiaquine Be Effective at Fighting COVID-19?

NIH Study Designed To Identify Promising COVID-19 Treatments for Larger Clinical Trials

ILC Therapeutics Announces COVID-19 Drug Development

Breaking COVID-19’s "Clutch" To Stop Its Spread

Team Identifies Small Molecules That Target SARS-CoV-2 RNA for Destruction

Could a Lipid Be Used To Prevent or Treat SARS-CoV-2 Infection?

REGN-COV2 Antibody Cocktail Reduced Viral Load and Alleviated Symptoms in Non-Hospitalized COVID-19 Patients

Phase 3 Trial Assesses Dual-Antibody Injection's Ability To Prevent SARS-CoV-2 Infection


Team Uncovers New Mechanism of Action Against SARS-CoV-2 by Remdesivir

Drug Shown To Modulate the Inflammatory Response in Severe COVID-19

Tiny Antibody Component Neutralizes SARS-CoV-2 in Animal Models

COVID-19 Phase 3 Trial To Evaluate REGN-COV2 Antibody Cocktail in UK

COVID-19 Drug Discovery and Development – Why Diverse Strategies Are Critical

Synthetic Antiviral Proteins Inhibit SARS-CoV-2 in Lab-Grown Human Cells

The Impact of Genetics on COVID-19 Treatments

Risk of Severe COVID-19 Was Reduced for Patients Taking Blood Pressure Drug

Treating COVID-19 – 21 Existing Drugs Shown To Stop Replication of SARS-CoV-2

Could Steroids Be Used To Combat COVID-19 in Severely Ill Patients?

Ebselen May Be Effective as a Weapon Against Key Coronavirus Enzyme

Machine Learning Approach Identifies Potential Drug Candidates To Treat COVID-19

Study Indicates a Lack of Diversity in COVID-19 Clinical Trials

Existing Alcoholism Drug Potentially Effective Against COVID-19

RLF-100 Trial Shows Rapid Recovery From Respiratory Failure in Critically Ill Patients With COVID-19

Trial Tests Cancer Drug’s Ability To Reduce Respiratory Symptoms of COVID-19

Phase 2 Trial Launched To Investigate LAM-002A as a Treatment for COVID-19

Seaweed Extract Surpasses Remdesivir at Blocking SARS-CoV-2 in Cell Models of COVID-19

Team Identifies 21 Existing Drugs That Stop Replication of SARS-CoV-2

Chloroquine Does Not Inhibit SARS-CoV-2 Infection of Human Lung CellS

Nitric Oxide May Help To Control the Replication and Spread of SARS-CoV-2

Positive Trial Results of SNG001 in Hospitalized COVID-19 Patients

Team Screens Millions of Active Substances Against SARS-CoV-2

Could Heparin Be Used To Stop SARS-CoV-2 From Infecting Human Cells?

Trial Assessing Antiviral Drug DAS181 Against COVID-19 Begins Enrolling Patients

Single Dose of Tocilizumab Linked to 45% Lower Risk of Dying Among COVID-19 Patients on Ventilators

Why Lopinavir and Hydroxychloroquine Are Ineffective in COVID-19 Patients

Additional Data Announced on Use of Remdesivir for Treatment of COVID-19

Compounds Target Key Enzyme Halting SARS-CoV-2 Replication

Hydroxychloroquine and Lopinavir/Ritonavir Treatment Arms for COVID-19 Discontinued

Peptide Combo Could Help Reduce Damage Caused By SARS-CoV-2

Molecules Identified That Shut Down SARS-CoV-2 Polymerase Reaction

Existing Drugs Could Stop SARS-CoV-2 From Hijacking Cells

Clinical Trial Investigates Alpha-1-Antitrypsin for Severe COVID-19 Infection

Lopinavir–Ritonavir: No Clinical Benefit in Hospitalized COVID-19 Patients Studied in RECOVERY Trial

Home-based COVID-19 Trial of Inhaled SNG001 Expanded

Remdesivir Is First COVID-19 Treatment Recommended for EU Authorization

Remdesivir for COVID-19 – Exploring Different Formulations, At-risk Populations and Clinical Progress

UTHealth Evaluates Effectiveness of Canakinumab at Preventing COVID-19-induced Cytokine Release Syndrome

Life-saving Drug for Ventilated COVID-19 Patients Uncovered by UK Experts

Accelerated Efforts To Repurpose Approved Drugs for COVID-19

Combination Drug Treatments for COVID-19 Show Promise in Cell-based Tests

Rheumatoid Arthritis Drug Could Be Repurposed To Treat COVID-19 Patients
Many “First-wave” COVID-19 Clinical Studies Have Significant Design Shortcomings, Says Study

Meet The Authors
Laura Elizabeth Lansdowne
Laura Elizabeth Lansdowne
Managing Editor
Molly Campbell
Molly Campbell
Science Writer
Advertisement